Dermatology

Several modalities found to be effective in the triage of psoriasis patients with musculoskeletal symptoms, according to a study presented at the 2017 American College of Rheumatology meeting.

Top news of the week from Specialty Pharmacy Times.

A fire ant toxin may lead to new medications for psoriasis.

For patients with psoriasis and/or psoriatic arthritis, actual-to-expected dosing ratios and costs were lower for etanercept than for ustekinumab.

Findings may lead to future treatments for patients with psoriasis and psoriatic arthritis.

All doses of atopic dermatitis drug achieved significant improvements in skin and itch conditions.

New ulcerative colitis and Crohn’s disease cases were uncommon in plaque psoriasis patients administered ixekizumab.

Lebrikizumab is a monoclonal antibody designed to specifically target interleukin 13 for patients with moderate-to-severe atopic dermatitis.

Lebrikizumab is a monoclonal antibody designed to treat atopic dermatitis.

Novel treatment effective against rheumatoid arthritis also produced a marked improvement in skin lesions caused by atopic dermatitis.

Adalimumab (Humira) biosimilar being tested as an interchangeable drug for plaque psoriasis.

Renflexis is indicated for the same inflammatory conditions as reference drug infliximab.

Renflexis is a biosimilar of Remicade, which treats inflammatory conditions, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

Tremfya is the first and only approved biologic that selectively blocks the interleukin-23 protein.

Tremfya found to achieve significantly clearer skin in moderate to severe plaque psoriasis.

Top articles of the week from Specialty Pharmacy Times.

Study will examine the safety and efficacy of tralokinumab monotherapy in treating atopic dermatitis.

Tralokinumab is a novel human monoclonal antibody that targets a cytokine key in the development of atopic dermatitis.

Erelzi (etanercept) indicated to treat multiple inflammatory conditions.

There are nearly 1000 products in development for dermatological conditions.

Psoriasis drugs Cosentyx and Taltz demonstrated significantly more remissions in patients with psoriasis.

Psoriasis drugs achieve positive effects in remission and health-related quality of life.

Agents fight cancer by temporarily loosening DNA, increasing the expression of tumor suppressors, and making the tumor more vulnerable.

Low-cost generic topical steroids could save Medicare $944.8 million.

Psoriasis is an itchy, uncomfortable, hyperproliferative dermatologic condition that tends to affect patients’ elbows, knees, scalp, umbilicus, lumbar regions, fingernails, toenails, and areas with skinfolds.

Adalimumab (Humira) demonstrated skin clearance among patients with fingernail psoriasis.

Women observed to have significantly lower Psoriasis Area Severity Index scores than men.

Injection helps clear skin and manage itch severity caused by the disease.

The FDA has approved Dupixent (dupilumab) injection, from Sanofi and Regeneron Pharmaceuticals, for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis (AD).

A majority of patients experienced the same level of skin clearing as initial treatment with Cosentyx.